Research finds higher stool oxalate levels in IBD patients despite similar diets — Evidence Review

Spinach, almonds, and sweet potatoes contain oxalate, a plant compound that new research from the UNC School of Medicine suggests may worsen intestinal inflammation in people with inflammatory bowel disease (IBD). Related studies largely support a link between dietary oxalate, gut inflammation, and impaired oxalate handling in IBD.

• Multiple studies confirm that oxalate metabolism and transport are disrupted in IBD, and that intestinal inflammation increases oxalate accumulation, supporting the new findings that elevated stool oxalate in IBD is not solely explained by diet 2 3.
• Research in animal models demonstrates that dietary oxalate and related compounds can exacerbate colitis and are associated with gut microbiota changes, which aligns with the new study’s mechanistic insights 1 2.
• The literature review highlights the importance of oxalate transporters and gut microbiota in oxalate handling and inflammation, consistent with the new study’s identification of reduced transporter gene expression and the potential for microbiome-based interventions 3.

Study Overview and Key Findings

Inflammatory bowel disease affects millions worldwide, yet the role of specific dietary components in modulating disease activity remains unclear. This study addresses a longstanding question: does oxalate—a common compound in many healthy plant foods—actively drive gut inflammation in genetically susceptible individuals? By integrating clinical data, dietary assessments, animal models, and molecular analyses, the research provides new evidence for oxalate’s involvement in IBD pathophysiology.

Property	Value
Study Year	2026
Organization	UNC School of Medicine, Texas A&M University, Duke University
Journal Name	Cellular and Molecular Gastroenterology and Hepatology
Authors	Anna Salvador, Shehzad Z. Sheikh
Population	People with inflammatory bowel disease (IBD), healthy controls
Methods	Animal Study
Outcome	Gene activity, oxalate levels, dietary patterns, inflammation
Results	IBD patients had higher stool oxalate despite similar diets.

The study, published in August 2026, investigated oxalate metabolism in IBD by measuring gene expression of oxalate transporters, stool oxalate concentration, and dietary patterns in both patients and controls. Key findings include:

• IBD patients—particularly those with Crohn’s disease—exhibited higher stool oxalate levels than healthy controls, despite consuming similar amounts of plant-based foods.
• Two oxalate transporter proteins, SLC26A2 and SLC26A3, showed consistently lower expression in affected intestinal tissue from IBD patients, irrespective of inflammation status.
• Animal experiments demonstrated that dietary oxalate exacerbated colitis severity and accelerated disease onset in genetically susceptible mice.
• Cell culture studies indicated that oxalate directly intensified immune cell inflammatory responses.
• Reduced expression of another transporter, SLC26A6, was associated with stricturing Crohn’s disease, suggesting potential as a marker for more aggressive disease.

Importantly, the study does not recommend that people with IBD avoid plant foods entirely. Rather, it suggests that impaired oxalate handling—due to genetic or disease-related factors—may make even moderate oxalate intake problematic in some individuals. The findings point to oxalate transporters and the gut microbiome as possible therapeutic targets, though further research is required before changing dietary guidelines.

Literature Review: Related Studies

To contextualize these findings, we searched the Consensus research paper database using targeted queries. The following search queries were used to identify relevant literature:

1. IBD stool oxalate levels diet comparison
2. healthy foods oxalate impact IBD
3. dietary oxalate effects inflammatory bowel disease

Below, we summarize key themes and findings from the related studies:

Topic	Key Findings
How does dietary oxalate and fat intake affect intestinal inflammation and hyperoxaluria?	- Dietary oxalate, especially when combined with intestinal inflammation or fat malabsorption, increases stool oxalate and worsens colitis in mouse models 2. - High-fat and oxalate-rich diets in the context of gut inflammation lead to hyperoxaluria and kidney injury, supporting a mechanistic link between diet, inflammation, and oxalate handling 2.
What is the role of oxalate transporters and gut microbiota in oxalate metabolism and IBD?	- Oxalate transporters (notably SLC26 family members) are key regulators of intestinal oxalate absorption and secretion; their dysfunction is implicated in hyperoxaluria and IBD 3. - Gut microbiota composition influences oxalate degradation; microbiome dysbiosis can promote oxalate accumulation and intestinal inflammation 1 3.
Can dietary components other than oxalate exacerbate colitis via gut microbiota changes?	- Dietary oxidized cholesterol increases susceptibility to colitis in mice by inducing gut microbiota dysbiosis and reducing beneficial bacteria, suggesting that various dietary molecules may modulate gut inflammation through microbiome effects 1. - Gut microbiota disturbances caused by specific dietary exposures can worsen inflammation independently of direct mucosal injury 1.
What are the clinical implications for managing hyperoxaluria and IBD?	- Multidisciplinary approaches targeting oxalate metabolism, transporters, and the gut-kidney axis are necessary for preventing complications like kidney stones in IBD patients 3. - The need for further randomized studies is emphasized to clarify the efficacy of targeting oxalate transport or the microbiome in IBD management 3.

How does dietary oxalate and fat intake affect intestinal inflammation and hyperoxaluria?

Several studies show that dietary oxalate and high-fat intake can significantly influence oxalate absorption and the severity of intestinal inflammation, especially in the context of underlying gut disease. The 2025 mouse model study found that both diet-induced obesity with high-fat, oxalate-rich diets and spontaneous ileitis led to increased stool oxalate, fat malabsorption, and kidney injury—findings that closely mirror the impaired oxalate handling observed in the new IBD study 2. This supports the notion that gut inflammation and fat malabsorption can amplify oxalate accumulation and related complications.

• High dietary oxalate in the setting of gut inflammation increases the risk of hyperoxaluria and worsens disease severity 2.
• Fat malabsorption, as seen after bariatric surgery or in chronic gut inflammation, further exacerbates oxalate accumulation 2.
• The relationship between diet, gut inflammation, and oxalate handling is complex, requiring consideration of both dietary intake and intestinal function 2.
• The new study’s findings align with these animal data, suggesting similar mechanisms may operate in human IBD.

What is the role of oxalate transporters and gut microbiota in oxalate metabolism and IBD?

The literature emphasizes the central role of oxalate transporters—particularly members of the SLC26 gene family—and the gut microbiome in regulating oxalate homeostasis. Disruption of these transporters in IBD patients, as documented in the new study, is consistent with reviews highlighting their importance in both oxalate absorption and secretion 3. Similarly, the abundance of oxalate-degrading bacteria, which is often reduced in IBD, can modulate oxalate levels and inflammation 1 3.

• SLC26 transporters (SLC26A2, SLC26A3, SLC26A6) are critical for oxalate movement across the intestinal epithelium 3.
• Dysfunction or reduced expression of these transporters contributes to hyperoxaluria in IBD 3.
• Microbiome composition, especially the presence of oxalate-degrading bacteria, can protect against oxalate accumulation and inflammation 1 3.
• Both the new and prior studies suggest that interventions targeting transporters or the microbiome could have therapeutic potential.

Can dietary components other than oxalate exacerbate colitis via gut microbiota changes?

Research also indicates that additional dietary factors—such as oxidized cholesterol—can promote colitis by altering the gut microbiota, independently of direct mucosal injury 1. This suggests that the inflammatory potential of specific dietary molecules may be modulated by their effects on the microbiome, a mechanism that may also apply to oxalate as demonstrated by the new study.

• Dietary oxidized cholesterol increases colitis severity by disturbing the gut microbiome, reducing beneficial bacteria, and increasing harmful species 1.
• Microbiota changes can mediate the impact of diet on gut inflammation, even in the absence of direct epithelial injury 1.
• Antibiotic treatment or microbiome transfer studies further support the role of microbiota in mediating diet-induced colitis 1.
• The new study’s focus on oxalate adds to this body of work, showing that multiple dietary components can influence gut inflammation via microbiome effects.

What are the clinical implications for managing hyperoxaluria and IBD?

The clinical literature underscores the need for multidisciplinary strategies to prevent complications such as kidney stones in IBD patients with hyperoxaluria 3. Both the new and existing studies highlight gaps in understanding the efficacy of targeting oxalate metabolism or transporters and the gut microbiome, pointing to the necessity of further clinical research before specific dietary or therapeutic recommendations are made.

• Understanding oxalate transport and metabolism is essential for developing interventions to prevent kidney stones and manage IBD-associated hyperoxaluria 3.
• The potential of targeting newly identified transporters (SLC26 family) or the gut microbiome remains to be fully explored 3.
• More randomized clinical trials are needed to inform evidence-based guidelines for diet and therapeutics in IBD 3.
• The new study strengthens the rationale for such future research by identifying molecular markers and mechanistic pathways involved in oxalate handling.

Future Research Questions

While the new study advances understanding of oxalate’s role in IBD, many questions remain regarding the mechanisms, clinical applications, and potential interventions. Further research is essential to determine whether modifying oxalate intake or targeting the microbiome can improve outcomes for IBD patients.

Research Question	Relevance
Does reducing dietary oxalate intake improve IBD outcomes?	Clarifying whether lowering oxalate intake can reduce inflammation or prevent disease progression is critical for developing evidence-based dietary guidelines for IBD patients 2 3.
Can modifying the gut microbiome enhance intestinal oxalate degradation in IBD?	Investigating whether interventions such as probiotics or microbiome transplantation can increase oxalate breakdown and reduce inflammation could offer non-dietary therapeutic strategies 1 3.
What genetic factors determine oxalate transporter expression in IBD?	Understanding the genetic regulation of oxalate transporters (e.g., SLC26A2, SLC26A3, SLC26A6) may help identify patients at highest risk and inform personalized treatment approaches 3.
How does fat malabsorption interact with oxalate metabolism in IBD?	Elucidating the interplay between dietary fat, malabsorption, and oxalate handling could help explain differences in disease severity and guide integrated dietary recommendations 2.
Are oxalate transporter levels predictive of IBD complications such as stricturing disease?	Determining whether transporter gene expression can predict disease course or complications may improve risk stratification and targeted monitoring in IBD management 3.

---

This article presents an objective overview of the latest research on dietary oxalate and its potential role in IBD, situating the findings within the broader scientific context and highlighting areas for future investigation.